Go to main content
Type 1
Type 2

Senseonics’ Eversense Bridge Program: Cost Assistance for 90-Day Implantable CGM

By Emma Ryan and Maeve Serino

Senseonics’ Eversense Bridge Program will offer the 90-day Eversense CGM at a reduced $99 price plus the cost of sensor insertion/removal

Senseonic’s Eversense continuous glucose monitor (CGM) includes a small, pill-sized sensor that is implanted in the upper arm for 90 days, an on-body transmitter, and a smartphone app for viewing blood glucose data. The manufacturer, Senseonics, recently announced the Eversense Bridge Program, which makes the Eversense CGM available for a discounted $99 to those who meet eligibility requirements. The program does not include the cost of sensor insertion or removal, which is determined by the healthcare provider but typically runs $200-300 for insertion and $300-400 for removal and reinsertion.

Because Eversense is a new-to-market CGM, Senseonics does not yet have broad insurance coverage in place. This program will help ease the startup cost for those waiting for coverage, provide assistance on confirming insurance benefits, and help with appeals.  This program applies to up to two sensors, each $99.

Am I eligible?

To qualify, you must:

  • Be 18 years or older;

  • Have a prescription for Eversense;

  • Not be fully covered for Eversense under your insurance;

  • Not be enrolled in any state or federally-funded insurance program (e.g., Medicare, Medicaid, Medicare Advantage, VA, DOD, TRICARE); and

  • Not be a resident of Massachusetts.

If you do not qualify for the Eversense Bridge Program, Senseonics’ distributor partners will work with you to see if you can obtain coverage under your insurance plan or through other programs.

How can I get started?

Eligible individuals should fill out a form on the Eversense website or call 1-844-736-7348.

What is Eversense?

Eversense is the first implantable CGM available in the US. A pill-sized sensor is implanted in the upper arm for 90 days, and an on-body transmitter sits on top of the skin and relays the real-time CGM data to a smartphone app (Apple or Android). This is in contrast to the Abbott Freestyle Libre, Dexcom G5/G6, and Medtronic Guardian Sensor 3, in which on-body sensors need to be replaced every 7-14 days.

Eversense must be calibrated with two fingersticks twice per day (Libre and G6 are no-calibration). Eversense CGM readings are not yet approved for dosing insulin, though Senseonics is currently pursuing that updated approval from the FDA.